<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="https://www.vetsurgeon.org/utility/feedstylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>Abstracts, Short Communications &amp; Research</title><link>https://www.vetsurgeon.org/w/veterinary-research</link><description>In this wiki, members may publish case studies and reports, presentations, short communications, research papers and the results of clinical audits relating to small animals, for open review / discussion by all members of VetSurgeon.</description><dc:language>en-US</dc:language><generator>Telligent Community 10</generator><item><title>Decision-Making in Spinal Cord Disease</title><link>https://www.vetsurgeon.org/w/veterinary-research/883/decision-making-in-spinal-cord-disease</link><pubDate>Tue, 14 Jul 2015 07:16:17 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:84dc35fa-d55b-4592-a29b-72c3e8402a80</guid><dc:creator>joanne mcallister</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by joanne mcallister on 7/14/2015 7:16:17 AM&lt;br /&gt;
&lt;p&gt;&lt;span style="display:block;" id="video_491ad22a-e0ab-41d7-843d-4d21e32b147d"&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>Abstracts, Short Communications &amp; Research</title><link>https://www.vetsurgeon.org/w/veterinary-research</link><pubDate>Thu, 02 Jul 2015 07:03:40 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:b070c1be-9312-4696-b01f-d82e1ae2beed</guid><dc:creator>Anonymous</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by Anonymous on 7/2/2015 7:03:40 AM&lt;br /&gt;
&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation</link><pubDate>Wed, 22 Jan 2014 23:00:37 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>grumpyoldman</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by grumpyoldman on 1/22/2014 11:00:37 PM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls on just a few because the code and its associated guidance are out of date and equivocal. Many vets do not offer 24/7 care but the code requires them to. (Visits and transfer of sick animals are both explored within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. Some sites pretend to offer 24/7 when in fact they farm it out. This helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably inappropriate PSS contract option - when you dont offer 24h care but want to be in the PSS. However it also seems to allow clinicians who dont have 24/7 care to fulfil code obligations to provide 24/7 to their patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr service. From a public and marketing point of view - these look similar&amp;nbsp; to big sites with lots of night staff - but they are not businesses that are fully staffed and they don&amp;#39;t have all the infrastructure and costs of 24 hr care. This advertising creep puts practices which have invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and anticompetitive. It takes little time to examine the websites of practices that use an EC or VH for their OOH and see how honest they appear. In some cases marketing appears to be a lie and if it is a lie, then&amp;nbsp; it is a matter that i already know trading standards will be very interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;24/7 OOH centers sites are commonly under-staffed and over-used by practices. The RCVS doesn&amp;#39;t state what is the maximum number of vets practices or registered clients that a OOH should be able to provide cover for. This leaves single vets in OOH centers having to make patients wait for too long in emergency consultations. And exposing themselves to complaint.&lt;/li&gt;
&lt;li&gt;Further relaxation of the requirement for all practices to make 
arrangements for 24/7 cover and for veterinary surgeons to visit when 
clinically necessary may result in considerable unnecessary 
animal suffering.&lt;/li&gt;
&lt;li&gt;If visits are to remain mandatory then it should also be mandatory that OOH centres are &lt;span style="text-decoration:underline;"&gt;always&lt;/span&gt;&amp;nbsp;staffed by two veterinary surgeons so that, if one is called to the mandatory visit, there is always a VS available to cover in-patients and emergencies that may present.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;The OOH service providers state in their literature that their vets are OOH specialists ,who are fresh faced and bushy tailed having not worked the previous day. But actually often they are just people who work for donor practices who are,moonlighting and are not speciaIsts in anything. They are in fact just doing a night shift for the extra income.&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;strong&gt;Should mandatory house visits be removed from the GTPC?&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;It is often impossible to know if a visit is &amp;#39;clinically&amp;#39; necessary on a phone conversation. &lt;/li&gt;
&lt;strong&gt;&lt;/strong&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;strong&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare / cause unnecessary suffering if, as a result of removing the requirement to visit at home from GTPC, veterinary surgeons fail to provide home visits.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;
&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;
&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;
&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/7</link><pubDate>Wed, 15 Jan 2014 10:51:26 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Anthony Todd</dc:creator><description>Revision 7 posted to Abstracts, Short Communications &amp;amp; Research by Anthony Todd on 1/15/2014 10:51:26 AM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls on just a few because the code and its associated guidance are out of date and equivocal. Many vets do not offer 24/7 care but the code requires them to. (Visits and transfer of sick animals are both explored within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. Some sites pretend to offer 24/7 when in fact they farm it out. This helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably inappropriate PSS contract option - when you dont offer 24h care but want to be in the PSS. However it also seems to allow clinicians who dont have 24/7 care to fulfil code obligations to provide 24/7 to their patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr service. From a public and marketing point of view - these look similar&amp;nbsp; to big sites with lots of night staff - but they are not businesses that are fully staffed and they don&amp;#39;t have all the infrastructure and costs of 24 hr care. This advertising creep puts practices which have invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and anticompetitive. It takes little time to examine the websites of practices that use an EC or VH for their OOH and see how honest they appear. In some cases marketing appears to be a lie and if it is a lie, then&amp;nbsp; it is a matter that i already know trading standards will be very interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;24/7 OOH centers sites are commonly under-staffed and over-used by practices. The RCVS doesn&amp;#39;t state what is the maximum number of vets practices or registered clients that a OOH should be able to provide cover for. This leaves single vets in OOH centers having to make patients wait for too long in emergency consultations. And exposing themselves to complaint.&lt;/li&gt;
&lt;li&gt;Further relaxation of the requirement for all practices to make 
arrangements for 24/7 cover and for veterinary surgeons to visit when 
clinically necessary may result in considerable unnecessary 
animal suffering.&lt;/li&gt;
&lt;li&gt;If visits are to remain mandatory then it should also be mandatory that OOH centres are &lt;span style="text-decoration:underline;"&gt;always&lt;/span&gt;&amp;nbsp;staffed by two veterinary surgeons so that, if one is called to the mandatory visit, there is always a VS available to cover in-patients and emergencies that may present.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;strong&gt;Should mandatory house visits be removed from the GTPC?&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;It is often impossible to know if a visit is &amp;#39;clinically&amp;#39; necessary on a phone conversation. &lt;/li&gt;
&lt;strong&gt;&lt;/strong&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;strong&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare / cause unnecessary suffering if, as a result of removing the requirement to visit at home from GTPC, veterinary surgeons fail to provide home visits.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;
&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;
&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;
&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/6</link><pubDate>Fri, 10 Jan 2014 12:37:51 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Arlo Guthrie</dc:creator><description>Revision 6 posted to Abstracts, Short Communications &amp;amp; Research by Arlo Guthrie on 1/10/2014 12:37:51 PM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls on just a few because the code and its associated guidance are out of date and equivocal. Many vets do not offer 24/7 care but the code requires them to. (Visits and transfer of sick animals are both explored within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. Some sites pretend to offer 24/7 when in fact they farm it out. This helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably inappropriate PSS contract option - when you dont offer 24h care but want to be in the PSS. However it also seems to allow clinicians who dont have 24/7 care to fulfil code obligations to provide 24/7 to their patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr service. From a public and marketing point of view - these look similar&amp;nbsp; to big sites with lots of night staff - but they are not businesses that are fully staffed and they don&amp;#39;t have all the infrastructure and costs of 24 hr care. This advertising creep puts practices which have invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and anticompetitive. It takes little time to examine the websites of practices that use an EC or VH for their OOH and see how honest they appear. In some cases marketing appears to be a lie and if it is a lie, then&amp;nbsp; it is a matter that i already know trading standards will be very interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;24/7 OOH centers sites are commonly under-staffed and over-used by practices. The RCVS doesn&amp;#39;t state what is the maximum number of vets practices or registered clients that a OOH should be able to provide cover for. This leaves single vets in OOH centers having to make patients wait for too long in emergency consultations. And exposing themselves to complaint.&lt;/li&gt;
&lt;li&gt;Further relaxation of the requirement for all practices to make 
arrangements for 24/7 cover and for veterinary surgeons to visit when 
clinically necessary may result in considerable unnecessary 
animal suffering.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;b&gt;Should mandatory house visits be removed from the GTPC?&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;It is often impossible to know if a visit is &amp;#39;clinically&amp;#39; necessary on a phone conversation. &lt;/li&gt;
&lt;b&gt;&lt;/b&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare / cause unnecessary suffering if, as a result of removing the requirement to visit at home from GTPC, veterinary surgeons fail to provide home visits.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/5</link><pubDate>Fri, 10 Jan 2014 12:03:03 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Arlo Guthrie</dc:creator><description>Revision 5 posted to Abstracts, Short Communications &amp;amp; Research by Arlo Guthrie on 1/10/2014 12:03:03 PM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls on just a few because the code and its associated guidance are out of date and equivocal. Many vets do not offer 24/7 care but the code requires them to. (Visits and transfer of sick animals are both explored within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. Some sites pretend to offer 24/7 when in fact they farm it out. This helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably inappropriate PSS contract option - when you dont offer 24h care but want to be in the PSS. However it also seems to allow clinicians who dont have 24/7 care to fulfil code obligations to provide 24/7 to their patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr service. From a public and marketing point of view - these look similar&amp;nbsp; to big sites with lots of night staff - but they are not businesses that are fully staffed and they don&amp;#39;t have all the infrastructure and costs of 24 hr care. This advertising creep puts practices which have invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and anticompetitive. It takes little time to examine the websites of practices that use an EC or VH for their OOH and see how honest they appear. In some cases marketing appears to be a lie and if it is a lie, then&amp;nbsp; it is a matter that i already know trading standards will be very interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;24/7 OOH centers sites are commonly under-staffed and over-used by practices. The RCVS doesn&amp;#39;t state what is the maximum number of vets practices or registered clients that a OOH should be able to provide cover for. This leaves single vets in OOH centers having to make patients wait for too long in emergency consultations. And exposing themselves to complaint.&lt;/li&gt;
&lt;li&gt;Further relaxation of the requirement for all practices to make 
arrangements for 24/7 cover and for veterinary surgeons to visit when 
clinically necessary may result in considerable unnecessary 
animal suffering.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;b&gt;Should mandatory house visits be removed from the GTPC?&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;It is often impossible to know if a visit is &amp;#39;clinically&amp;#39; necessary on a phone conversation. &lt;/li&gt;
&lt;b&gt;&lt;/b&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare / cause unnecessary suffering if animals fail to get treatment as quickly as they might otherwise.&amp;nbsp;&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/4</link><pubDate>Fri, 10 Jan 2014 11:54:47 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Hannah Wynne Richards</dc:creator><description>Revision 4 posted to Abstracts, Short Communications &amp;amp; Research by Hannah Wynne Richards on 1/10/2014 11:54:47 AM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls on just a few because the code and its associated guidance are out of date and equivocal. Many vets do not offer 24/7 care but the code requires them to. (Visits and transfer of sick animals are both explored within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. Some sites pretend to offer 24/7 when in fact they farm it out. This helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably inappropriate PSS contract option - when you dont offer 24h care but want to be in the PSS. However it also seems to allow clinicians who dont have 24/7 care to fulfil code obligations to provide 24/7 to their patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr service. From a public and marketing point of view - these look similar&amp;nbsp; to big sites with lots of night staff - but they are not businesses that are fully staffed and they don&amp;#39;t have all the infrastructure and costs of 24 hr care. This advertising creep puts practices which have invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and anticompetitive. It takes little time to examine the websites of practices that use an EC or VH for their OOH and see how honest they appear. In some cases marketing appears to be a lie and if it is a lie, then&amp;nbsp; it is a matter that i already know trading standards will be very interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;24/7 OOH centers sites are commonly under-staffed and over-used by practices. The RCVS doesn&amp;#39;t state what is the maximum number of vets practices or registered clients that a OOH should be able to provide cover for. This leaves single vets in OOH centers having to make patients wait for too long in emergency consultations. And exposing themselves to complaint.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;b&gt;Should mandatory house visits be removed from the GTPC?&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;It is often impossible to know if a visit is &amp;#39;clinically&amp;#39; necessary on a phone conversation. &lt;/li&gt;
&lt;b&gt;&lt;/b&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare if animals fail to get treatment as quickly as they might otherwise.&amp;nbsp;&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;Further relaxation of the requirement for all practices to make arrangements for 24/7 cover and for veterinary surgeons to visit when clinically necessary will inevitably result in considerable unnecessary animal suffering, and so should be unequivocally opposed.&lt;/p&gt;
&lt;p&gt;H W Richards&lt;/p&gt;
&lt;p&gt;Penybryn Veterinary Cente&lt;/p&gt;
&lt;p&gt;7/7 Sketty Ave&lt;/p&gt;
&lt;p&gt;Swansea&lt;/p&gt;
&lt;p&gt;SA2 0TE&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/3</link><pubDate>Fri, 10 Jan 2014 10:34:29 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Francisco Gomez</dc:creator><description>Revision 3 posted to Abstracts, Short Communications &amp;amp; Research by Francisco Gomez on 1/10/2014 10:34:29 AM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls 
on just a few because the code and its associated guidance are out of 
date and equivocal. Many vets do not offer 24/7 care but the code 
requires them to. (Visits and transfer of sick animals are both explored
 within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. 
Some sites pretend to offer 24/7 when in fact they farm it out. This 
helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably 
inappropriate PSS contract option - when you dont offer 24h care but 
want to be in the PSS. However it also seems to allow clinicians who 
dont have 24/7 care to fulfil code obligations to provide 24/7 to their 
patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr 
service. From a public and marketing point of view - these look similar&amp;nbsp;
 to big sites with lots of night staff - but they are not businesses 
that are fully staffed and they don&amp;#39;t have all the infrastructure and 
costs of 24 hr care. This advertising creep puts practices which have 
invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and 
anticompetitive. It takes little time to examine the websites of 
practices that use an EC or VH for their OOH and see how honest they 
appear. In some cases marketing appears to be a lie and if it is a lie, 
then&amp;nbsp; it is a matter that i already know trading standards will be very 
interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS 
review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;24/7 OOH centers sites are commonly under-staffed and over-used by practices. The RCVS doesn&amp;#39;t state what is the maximum number of vets practices or registered clients that a OOH should be able to provide cover for. This leaves single vets in OOH centers having to make patients wait for too long in emergency consultations. And exposing themselves to complaint.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;b&gt;Should mandatory house visits be removed from the GTPC?&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;It is often impossible to know if a visit is &amp;#39;clinically&amp;#39; necessary on a phone conversation. &lt;/li&gt;
&lt;b&gt;
&lt;/b&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare if animals fail to get treatment as quickly as they might otherwise.&amp;nbsp;&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/2</link><pubDate>Fri, 10 Jan 2014 10:00:32 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Arlo Guthrie</dc:creator><description>Revision 2 posted to Abstracts, Short Communications &amp;amp; Research by Arlo Guthrie on 1/10/2014 10:00:32 AM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to. To do so, press the EDIT tab at the top of the page.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE any existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls 
on just a few because the code and its associated guidance are out of 
date and equivocal. Many vets do not offer 24/7 care but the code 
requires them to. (Visits and transfer of sick animals are both explored
 within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. 
Some sites pretend to offer 24/7 when in fact they farm it out. This 
helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably 
inappropriate PSS contract option - when you dont offer 24h care but 
want to be in the PSS. However it also seems to allow clinicians who 
dont have 24/7 care to fulfil code obligations to provide 24/7 to their 
patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr 
service. From a public and marketing point of view - these look similar&amp;nbsp;
 to big sites with lots of night staff - but they are not businesses 
that are fully staffed and they don&amp;#39;t have all the infrastructure and 
costs of 24 hr care. This advertising creep puts practices which have 
invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and 
anticompetitive. It takes little time to examine the websites of 
practices that use an EC or VH for their OOH and see how honest they 
appear. In some cases marketing appears to be a lie and if it is a lie, 
then&amp;nbsp; it is a matter that i already know trading standards will be very 
interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS 
review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;b&gt;Should mandatory house visits be removed from the GTPC?&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;b&gt;
&lt;/b&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare if animals fail to get treatment as quickly as they might otherwise.&amp;nbsp;&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>24/7 and OOH Home Visits Consultation</title><link>https://www.vetsurgeon.org/w/veterinary-research/1162/24-7-and-ooh-home-visits-consultation/revision/1</link><pubDate>Fri, 10 Jan 2014 09:59:44 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:02dbd27d-6606-43c7-b8ec-5bf9f5aaa643</guid><dc:creator>Arlo Guthrie</dc:creator><description>Revision 1 posted to Abstracts, Short Communications &amp;amp; Research by Arlo Guthrie on 1/10/2014 9:59:44 AM&lt;br /&gt;
&lt;p&gt;The RCVS has &lt;a href="/blogs/veterinary_news/archive/2013/12/31/103583.aspx"&gt;called for evidence concerning the provision of 24 hr emergency cover&lt;/a&gt;. &lt;/p&gt;
&lt;p&gt;This wiki page is a collaborative document which all members of vetsurgeon.org are invited to contribute to.&lt;/p&gt;
&lt;p&gt;The rules are simple. If you feel you can ADD an additional valid point to those listed below, please do. &lt;/p&gt;
&lt;p&gt;Please DO NOT DELETE an existing content you see on the page. &lt;/p&gt;
&lt;p&gt;There are two parts to this document which you might like to contribute to. First a list of issues you think the RCVS should consider as they review 24/7 cover, and secondly whether you think that the requirement to provide home visits should be removed. &lt;/p&gt;
&lt;p&gt;This page will be submitted to the RCVS on 17th February&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:large;"&gt;List of issues the RCVS should consider when reviewing the provision of 24/7 emergency cover:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;At present, the professional responsibility for night visits falls 
on just a few because the code and its associated guidance are out of 
date and equivocal. Many vets do not offer 24/7 care but the code 
requires them to. (Visits and transfer of sick animals are both explored
 within Chikosi and Gillams 2013) &lt;/li&gt;
&lt;li&gt;The present Code fudge leaves all unable to agree what is expected. 
Some sites pretend to offer 24/7 when in fact they farm it out. This 
helps their marketing, but is a breach of consumer trust .&lt;/li&gt;
&lt;li&gt;Claiming 24/7 service when you close at 6 utilises a probably 
inappropriate PSS contract option - when you dont offer 24h care but 
want to be in the PSS. However it also seems to allow clinicians who 
dont have 24/7 care to fulfil code obligations to provide 24/7 to their 
patients. &lt;/li&gt;
&lt;li&gt;You can be a VH without a 24/7 service.. is that OK? &lt;/li&gt;
&lt;li&gt;Some practices very close to a full 24/7 VH or EC advertise a 24hr 
service. From a public and marketing point of view - these look similar&amp;nbsp;
 to big sites with lots of night staff - but they are not businesses 
that are fully staffed and they don&amp;#39;t have all the infrastructure and 
costs of 24 hr care. This advertising creep puts practices which have 
invested money, time, resources and effort at disadvantage.&amp;nbsp; &lt;/li&gt;
&lt;li&gt;Present 24/7 claims and advertising are often misleading and 
anticompetitive. It takes little time to examine the websites of 
practices that use an EC or VH for their OOH and see how honest they 
appear. In some cases marketing appears to be a lie and if it is a lie, 
then&amp;nbsp; it is a matter that i already know trading standards will be very 
interested&amp;nbsp; in&amp;nbsp; - that is - if it is not sorted out at the next RCVS 
review &amp;quot;effectively&amp;quot;. &lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="font-size:large;"&gt;&lt;b&gt;Should mandatory house visits be removed from the GTPC?&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments for&lt;br /&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Would help reinforce the perception that owners have a responsibility for their own animals.&lt;/li&gt;
&lt;li&gt;Could improve animal welfare, as animals can often be better treated in practice than at home.&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;b&gt;
&lt;/b&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;b&gt;&lt;span style="font-size:medium;"&gt;Arguments against&lt;/span&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Could compromise animal welfare if animals fail to get treatment as quickly as they might otherwise.&amp;nbsp;&lt;/li&gt;
&lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>Innovative treatment for Feline fibrosarcoma to be launched this autumn</title><link>https://www.vetsurgeon.org/w/veterinary-research/88/innovative-treatment-for-feline-fibrosarcoma-to-be-launched-this-autumn</link><pubDate>Thu, 13 Jun 2013 15:13:15 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:493a21f5-d73a-4fac-80ee-8d4f00aac816</guid><dc:creator>kdelange</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by kdelange on 6/13/2013 3:13:15 PM&lt;br /&gt;
&lt;p&gt;&lt;span style="font-weight:normal;"&gt;&lt;span lang="EN-GB"&gt;Lisbon, 29 May 2013 - &amp;ldquo;&lt;i&gt;On average, European veterinary
practitioners see between two and three cases of feline fibrosarcoma each year&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; reported Pascal Fayard, European marketing manager, citing a
survey held among 500 general practitioners in five countries. Speaking at a
Merial Conference held in Lisbon on 29 of May, on the eve of the congress of
European Society of Veterinary Oncology, he announced the European-wide launch,
coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the
treatment of fibrosarcoma in cats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&lt;a href="/cfs-file.ashx/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg"&gt;&lt;img border="0" src="/resized-image.ashx/__size/550x0/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg" alt="" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;i&gt;Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&amp;amp;D Merial), Catherine P&amp;eacute;pin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion animals, Merial), Ana Lara (Royal Veterinary College, London), Herv&amp;eacute; Poulet (R&amp;amp;D Merial), Jolle Kirpensteijn (Utrecht University, moderator).&lt;/i&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;Interleukin: stimulating anti-tumour
defense&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;Interleukin 2 (IL-2) stimulates the
growth and activity of T-lymphocytes and natural killer cells, the production of
other cytokines like interferon gamma (IFN&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;&lt;span&gt;g&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;) and improves the specific tumour-protective memory immune
response&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; explained Herv&amp;eacute; Poulet, Head of bio
development Europe and R&amp;amp;D leader at Merial. &amp;ldquo;&lt;i&gt;In humans, high-dose
systemic IL-2 has been approved for the treatment of metastatic melanoma and
renal cell carcinoma&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, large doses of systemic IL-2 are
associated with several toxic side effects, including the capillary leak
syndrome while its clinical efficacy is hampered by the short half-life of IL-2
(a few days). To overcome this, several local IL-2-delivery systems have been
studied, including free recombinant IL-2, or bound to DNA plasmids, viral
vectors, IL-2 secreting cells and antibody-targeted IL. The therapeutic effects
of local IL-2 therapy have been demonstrated in several cancers, including
equine sarcoids, canine melanoma and non-resectable mast cell tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;For feline fibrosarcoma, we chose an
IL-2 expressing canarypox virus vector (ALVAC&lt;sup&gt;&amp;reg;&lt;/sup&gt;): it is very safe as
it does not replicate and expresses IL-2 locally. It was found to be an
efficacious adjunct treatment to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; Dr Poulet concluded.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Reducing the risk of relapse by 65%&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Results of a monocentric controlled clinical trial
were presented by Dominique Jas (Merial R&amp;amp;D) to confirm the efficacy and
safety of the product. Seventy-one cats with a first occurrence of feline
fibrosarcoma were referred for post-surgical radiotherapy. They were assigned
to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2
treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery
+ radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not
necessarily done in referral practices. However, the percentage of cats with
dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14, D21, D35, D49) was initiated the day before the start of radiotherapy (D1 and D3).
Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24
months. The high-dose group &amp;ndash; to test safety &amp;ndash; was monitored for a year, the
low-dose group &amp;ndash; to test efficacy &amp;ndash; for two years.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Local ALVAC IL-2-treated cats showed a
significantly longer median time to relapse (&amp;gt;730 days) than in the
reference treatment group (287 days). Results also showed a significant
reduction of relapse risk compared to the control group, both after one year
(56%) and after two years (65%). Oncept IL-2 was well tolerated, and the time
without relapse was significantly increased with no alteration of quality of
life.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;This study showed that the control
group, that did not undergo immunotherapy, did had poorer results than either
treatment group &amp;ndash; in spite of the cats receiving a total of thirty injections&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;quot; Dr Jas confirmed, in answer to the question whether
treatment injections were not a risk factors for the development of FISS. &lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Colleagues from Spain, where there is no
radiotherapy available for pets, asked about the possible benefits in cats with
surgery alone. &amp;ldquo;&lt;i&gt;We currently only have a claim for an adjunct therapy to surgery
and radiotherapy,&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt; stressed Dr Jas, but she added
that this was currently being investigated.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;An EU-wide launch this autumn&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We&amp;rsquo;re very excited and proud to announce
the forthcoming launch of a new immunotherapy, a recombinant canarypox virus
expressing feline IL-2 at the site of injection, added Catherine P&amp;eacute;pin,
Merial&amp;rsquo;s technical manager for companion animals. &amp;ldquo;The claim is for an adjunct
treatment in cats with fibrosarcoma (2-5 cm diameter) without metastasis or
lymph node involvement, in order to reduce the risk of relapse and to increase
the relapse-free interval.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Oncept IL-2, result of a long-standing
collaboration between Merial R&amp;amp;D and leading oncology experts, is the first
cancer immunotherapeutic drug approved for veterinary use in Europe.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We expect to launch Oncept IL-2 throughout
the EU this coming autumn, added Pascal Fayard. He also presented the packaging
(&amp;ldquo;&lt;i&gt;one box contains 6 doses, equal to one course of treatment&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;) and storage requirements (&amp;ldquo;&lt;i&gt;in the refrigerator, just like
vaccines&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;). However, the expected retail price was
not yet known &amp;ndash; but would no doubt be &amp;ldquo;&lt;i&gt;well over a hundred euros&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Oncept IL-2:&amp;nbsp;Six sessions, five injections, one
treatment&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Six sessions with local infiltration (five injections each) in the
tumour scar tissue are required. The product&amp;rsquo;s claim is specific: &amp;ldquo;&lt;i&gt;reducing
the risk of relapse and increasing the time to relapse in cats with
fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in
addition to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;After reconstitution, five subcutaneous
injections (0.2 ml each) are made in and around the tumour excision site: &amp;ldquo;&lt;i&gt;one
injection at each corner and one injection at the centre of a 5 cm x 5 cm
square centered on the middle of the surgical scar&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;A treatment course consists of four
sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment
sessions at 2-week intervals (D35, D49). Treatment is started the day before
commencing radiation therapy, preferably within one month after surgical
excision.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, no particular precautions are
necessary for administration, as &amp;ldquo;&lt;i&gt;canarypox recombinants are safe, and
feline IL-2 has a very low biological activity in humans&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;First surgical attempt = main prognostic
factor&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;An association between injections and
the development of feline injection-site sarcomas (FISS) was first observed in
the 1980s&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;, recalled Ana Lara (Royal Veterinary
College, UK). Subsequent studies showed a link with a range of injectable drugs
triggering local inflammation followed by an abnormal proliferation of
fibroblasts and myofibroblasts. &amp;ldquo;&lt;i&gt;These sarcomas were found to be highly
locally infiltrative but with a relatively low (0-24%) metastatic rate&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Although it is a neoplasia that is associated to veterinary
practice, there is a potential for prevention and early diagnosis: &amp;ldquo;&lt;i&gt;we know
the risk-population (those receiving injections) and the location (site of
injection)&amp;rdquo;. &lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;For these reasons, a benefit-risk
analysis is required prior to vaccination while vaccinate in the distal
extremities should be considered to maximise the chance of cure in the advent
of FISS.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;If FISS is suspected, never perform
excisional biopsy - it has a detrimental impact on prognosis&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; warned Dr Lara. &amp;ldquo;&lt;i&gt;In fact, the number one prognostic factor is
the first attempt at surgery - which should be aggressive: margins should be
4-5 cm wide and at least 2 fascial layers deep&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;She also recalled the 3-2-1 rule: &amp;ldquo;&lt;i&gt;biopsy
if the lump persists for more than 3 months, if it is larger than 2 cm or if it
has appeared within 1 month of injection&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Adding
radiotherapy increases the disease-free interval, but not the cure rate &amp;ndash; and
is not available in all European countries. Chemotherapy is only of interest in
cats with unresectable or metastatic tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;bull;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span style="text-decoration:underline;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;

&lt;div style="font-size: 90%;"&gt;Tags: sarcoma, Oncology, fibroma, fibrosarcoma, immunotherapy, Cats&lt;/div&gt;
</description></item><item><title>Innovative treatment for Feline fibrosarcoma to be launched this autumn</title><link>https://www.vetsurgeon.org/w/veterinary-research/88/innovative-treatment-for-feline-fibrosarcoma-to-be-launched-this-autumn/revision/6</link><pubDate>Thu, 13 Jun 2013 15:12:38 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:493a21f5-d73a-4fac-80ee-8d4f00aac816</guid><dc:creator>kdelange</dc:creator><description>Revision 6 posted to Abstracts, Short Communications &amp;amp; Research by kdelange on 6/13/2013 3:12:38 PM&lt;br /&gt;
&lt;p&gt;&lt;span style="font-weight:normal;"&gt;&lt;span lang="EN-GB"&gt;Lisbon, 29 May 2013 - &amp;ldquo;&lt;i&gt;On average, European veterinary
practitioners see between two and three cases of feline fibrosarcoma each year&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; reported Pascal Fayard, European marketing manager, citing a
survey held among 500 general practitioners in five countries. Speaking at a
Merial Conference held in Lisbon on 29 of May, on the eve of the congress of
European Society of Veterinary Oncology, he announced the European-wide launch,
coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the
treatment of fibrosarcoma in cats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&lt;a href="/cfs-file.ashx/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg"&gt;&lt;img src="/resized-image.ashx/__size/550x0/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg" border="0" alt="" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;i&gt;Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&amp;amp;D Merial), Catherine P&amp;eacute;pin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion animals, Merial), Ana Lara (Royal Veterinary College, London), Herv&amp;eacute; Poulet (R&amp;amp;D Merial), Jolle Kirpensteijn (Utrecht University, moderator).&lt;/i&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;Interleukin: stimulating anti-tumour
defense&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;Interleukin 2 (IL-2) stimulates the
growth and activity of T-lymphocytes and natural killer cells, the production of
other cytokines like interferon gamma (IFN&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;&lt;span&gt;g&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;) and improves the specific tumour-protective memory immune
response&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; explained Herv&amp;eacute; Poulet, Head of bio
development Europe and R&amp;amp;D leader at Merial. &amp;ldquo;&lt;i&gt;In humans, high-dose
systemic IL-2 has been approved for the treatment of metastatic melanoma and
renal cell carcinoma&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, large doses of systemic IL-2 are
associated with several toxic side effects, including the capillary leak
syndrome while its clinical efficacy is hampered by the short half-life of IL-2
(a few days). To overcome this, several local IL-2-delivery systems have been
studied, including free recombinant IL-2, or bound to DNA plasmids, viral
vectors, IL-2 secreting cells and antibody-targeted IL. The therapeutic effects
of local IL-2 therapy have been demonstrated in several cancers, including
equine sarcoids, canine melanoma and non-resectable mast cell tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;For feline fibrosarcoma, we chose an
IL-2 expressing canarypox virus vector (ALVAC&lt;sup&gt;&amp;reg;&lt;/sup&gt;): it is very safe as
it does not replicate and expresses IL-2 locally. It was found to be an
efficacious adjunct treatment to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; Dr Poulet concluded.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Reducing the risk of relapse by 65%&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Results of a monocentric controlled clinical trial
were presented by Dominique Jas (Merial R&amp;amp;D) to confirm the efficacy and
safety of the product. Seventy-one cats with a first occurrence of feline
fibrosarcoma were referred for post-surgical radiotherapy. They were assigned
to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2
treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery
+ radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not
necessarily done in referral practices. However, the percentage of cats with
dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14, D21, D35, D49) was initiated the day before the start of radiotherapy (D1 and D3).
Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24
months. The high-dose group &amp;ndash; to test safety &amp;ndash; was monitored for a year, the
low-dose group &amp;ndash; to test efficacy &amp;ndash; for two years.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Local ALVAC IL-2-treated cats showed a
significantly longer median time to relapse (&amp;gt;730 days) than in the
reference treatment group (287 days). Results also showed a significant
reduction of relapse risk compared to the control group, both after one year
(56%) and after two years (65%). Oncept IL-2 was well tolerated, and the time
without relapse was significantly increased with no alteration of quality of
life.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;This study showed that the control
group, that did not undergo immunotherapy, did had poorer results than either
treatment group &amp;ndash; in spite of the cats receiving a total of thirty injections&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;quot; Dr Jas confirmed, in answer to the question whether
treatment injections were not a risk factors for the development of FISS. &lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Colleagues from Spain, where there is no
radiotherapy available for pets, asked about the possible benefits in cats with
surgery alone. &amp;ldquo;&lt;i&gt;We currently only have a claim for an adjunct therapy to surgery
and radiotherapy,&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt; stressed Dr Jas, but she added
that this was currently being investigated.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;An EU-wide launch this autumn&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We&amp;rsquo;re very excited and proud to announce
the forthcoming launch of a new immunotherapy, a recombinant canarypox virus
expressing feline IL-2 at the site of injection, added Catherine P&amp;eacute;pin,
Merial&amp;rsquo;s technical manager for companion animals. &amp;ldquo;The claim is for an adjunct
treatment in cats with fibrosarcoma (2-5 cm diameter) without metastasis or
lymph node involvement, in order to reduce the risk of relapse and to increase
the relapse-free interval.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Oncept IL-2, result of a long-standing
collaboration between Merial R&amp;amp;D and leading oncology experts, is the first
cancer immunotherapeutic drug approved for veterinary use in Europe.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We expect to launch Oncept IL-2 throughout
the EU this coming autumn, added Pascal Fayard. He also presented the packaging
(&amp;ldquo;&lt;i&gt;one box contains 6 doses, equal to one course of treatment&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;) and storage requirements (&amp;ldquo;&lt;i&gt;in the refrigerator, just like
vaccines&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;). However, the expected retail price was
not yet known &amp;ndash; but would no doubt be &amp;ldquo;&lt;i&gt;well over a hundred euros&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Oncept IL-2:&amp;nbsp;Six sessions, five injections, one
treatment&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Six sessions with local infiltration (five injections each) in the
tumour scar tissue are required. The product&amp;rsquo;s claim is specific: &amp;ldquo;&lt;i&gt;reducing
the risk of relapse and increasing the time to relapse in cats with
fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in
addition to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;After reconstitution, five subcutaneous
injections (0.2 ml each) are made in and around the tumour excision site: &amp;ldquo;&lt;i&gt;one
injection at each corner and one injection at the centre of a 5 cm x 5 cm
square centered on the middle of the surgical scar&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;A treatment course consists of four
sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment
sessions at 2-week intervals (D35, D49). Treatment is started the day before
commencing radiation therapy, preferably within one month after surgical
excision.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, no particular precautions are
necessary for administration, as &amp;ldquo;&lt;i&gt;canarypox recombinants are safe, and
feline IL-2 has a very low biological activity in humans&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;First surgical attempt = main prognostic
factor&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;An association between injections and
the development of feline injection-site sarcomas (FISS) was first observed in
the 1980s&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;, recalled Ana Lara (Royal Veterinary
College, UK). Subsequent studies showed a link with a range of injectable drugs
triggering local inflammation followed by an abnormal proliferation of
fibroblasts and myofibroblasts. &amp;ldquo;&lt;i&gt;These sarcomas were found to be highly
locally infiltrative but with a relatively low (0-24%) metastatic rate&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Although it is a neoplasia that is associated to veterinary
practice, there is a potential for prevention and early diagnosis: &amp;ldquo;&lt;i&gt;we know
the risk-population (those receiving injections) and the location (site of
injection)&amp;rdquo;. &lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;For these reasons, a benefit-risk
analysis is required prior to vaccination while vaccinate in the distal
extremities should be considered to maximise the chance of cure in the advent
of FISS.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;If FISS is suspected, never perform
excisional biopsy - it has a detrimental impact on prognosis&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; warned Dr Lara. &amp;ldquo;&lt;i&gt;In fact, the number one prognostic factor is
the first attempt at surgery - which should be aggressive: margins should be
4-5 cm wide and at least 2 fascial layers deep&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;She also recalled the 3-2-1 rule: &amp;ldquo;&lt;i&gt;biopsy
if the lump persists for more than 3 months, if it is larger than 2 cm or if it
has appeared within 1 month of injection&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Adding
radiotherapy increases the disease-free interval, but not the cure rate &amp;ndash; and
is not available in all European countries. Chemotherapy is only of interest in
cats with unresectable or metastatic tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;bull;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span style="text-decoration:underline;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;

&lt;div style="font-size: 90%;"&gt;Tags: cats, sarcoma, fibroma, fibrosarcoma, oncology, immunotherapy&lt;/div&gt;
</description></item><item><title>Innovative treatment for Feline Injection Site Sarcoma to be launched this autumn</title><link>https://www.vetsurgeon.org/w/veterinary-research/88/innovative-treatment-for-feline-fibrosarcoma-to-be-launched-this-autumn/revision/5</link><pubDate>Tue, 11 Jun 2013 13:13:37 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:493a21f5-d73a-4fac-80ee-8d4f00aac816</guid><dc:creator>kdelange</dc:creator><description>Revision 5 posted to Abstracts, Short Communications &amp;amp; Research by kdelange on 6/11/2013 1:13:37 PM&lt;br /&gt;
&lt;p&gt;&lt;span style="font-weight:normal;"&gt;&lt;span lang="EN-GB"&gt;Lisbon, 29 May 2013 - &amp;ldquo;&lt;i&gt;On average, European veterinary
practitioners see between two and three cases of feline sarcoma each year&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; reported Pascal Fayard, European marketing manager, citing a
survey held among 500 general practitioners in five countries. Speaking at a
Merial Conference held in Lisbon on 29 of May, on the eve of the congress of
European Society of Veterinary Oncology, he announced the European-wide launch,
coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the
treatment of fibrosarcoma in cats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&lt;a href="/cfs-file.ashx/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg"&gt;&lt;img border="0" src="/resized-image.ashx/__size/550x0/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg" alt="" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;i&gt;Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&amp;amp;D Merial), Catherine P&amp;eacute;pin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion animals, Merial), Ana Lara (Royal Veterinary College, London), Herv&amp;eacute; Poulet (R&amp;amp;D Merial), Jolle Kirpensteijn (Utrecht University, moderator).&lt;/i&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;Interleukin: stimulating anti-tumour
defence&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;Interleukin 2 (IL-2) stimulates the
growth and activity of T-lymphocytes and natural killer cells, the production of
other cytokines like interferon gamma (IFN&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;&lt;span&gt;g&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;) and improves the specific tumour-protective memory immune
response&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; explained Herv&amp;eacute; Poulet, Head of bio
development Europe and R&amp;amp;D leader at Merial. &amp;ldquo;&lt;i&gt;In humans, high-dose
systemic IL-2 has been approved for the treatment of metastatic melanoma and
renal cell carcinoma&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, large doses of systemic IL-2 are
associated with several toxic side effects, including the capillary leak
syndrome while its clinical efficacy is hampered by the short half-life of IL-2
(a few days). To overcome this, several local IL-2-delivery systems have been
studied, including free recombinant IL-2, or bound to DNA plasmids, viral
vectors, IL-2 secreting cells and antibody-targeted IL. The therapeutic effects
of local IL-2 therapy have been demonstrated in several cancers, including
equine sarcoids, canine melanoma and non-resectable mast cell tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;For feline fibrosarcoma, we chose an
IL-2 expressing canarypox virus vector (ALVAC&lt;sup&gt;&amp;reg;&lt;/sup&gt;): it is very safe as
it does not replicate and expresses IL-2 locally. It was found to be an
efficacious adjunct treatment to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; Dr Poulet concluded.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Reducing the risk of relapse by 65%&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Results of a monocentric clinical trial
were presented by Dominique Jas (Merial R&amp;amp;D) to confirm the efficacy and
safety of the product. Seventy-one cats with a first occurrence of feline
fibrosarcoma were referred for post-surgical radiotherapy. They were assigned
to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2
treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery
+ radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not
necessarily done in referral practices. However, the percentage of cats with
dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14,
D35, D49) was initiated the day before the start of radiotherapy (D1 and D3).
Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24
months. The high-dose group &amp;ndash; to test safety &amp;ndash; was monitored for a year, the
low-dose group &amp;ndash; to test efficacy &amp;ndash; for two years.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Local ALVAC IL-2-treated cats showed a
significantly longer median time to relapse (&amp;gt;730 days) than in the
reference treatment group (287 days). Results also showed a significant
reduction of relapse risk compared to the control group, both after one year
(56%) and after two years (65%). Oncept IL-2 was well tolerated, and the time
without relapse was significantly increased with no alteration of quality of
life.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;This study showed that the control
group, that did not undergo immunotherapy, did had poorer results than either
treatment group &amp;ndash; in spite of the cats receiving a total of thirty injections&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;quot; Dr Jas confirmed, in answer to the question whether
treatment injections were not a risk factors for the development of FISS. &lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Colleagues from Spain, where there is no
radiotherapy available for pets, asked about the possible benefits in cats with
surgery alone. &amp;ldquo;&lt;i&gt;We currently only have a claim for an adjunct therapy to surgery
and radiotherapy,&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt; stressed Dr Jas, but she added
that this was currently being investigated.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;An EU-wide launch this autumn&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We&amp;rsquo;re very excited and proud to announce
the forthcoming launch of a new immunotherapy, a recombinant canarypox virus
expressing feline IL-2 at the site of injection, added Catherine P&amp;eacute;pin,
Merial&amp;rsquo;s technical manager for companion animals. &amp;ldquo;The claim is for an adjunct
treatment in cats with fibrosarcoma (2-5 cm diameter) without metastasis or
lymph node involvement, in order to reduce the risk of relapse and to increase
the relapse-free interval.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Oncept IL-2, result of a long-standing
collaboration between Merial R&amp;amp;D and leading oncology experts, is the first
cancer immunotherapeutic drug approved for veterinary use in Europe.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We expect to launch Oncept IL-2 throughout
the EU this coming autumn, added Pascal Fayard. He also presented the packaging
(&amp;ldquo;&lt;i&gt;one box contains 6 doses, equal to one course of treatment&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;) and storage requirements (&amp;ldquo;&lt;i&gt;in the refrigerator, just like
vaccines&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;). However, the expected retail price was
not yet known &amp;ndash; but would no doubt be &amp;ldquo;&lt;i&gt;well over a hundred euros&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Oncept IL-2:&amp;nbsp;Six sessions, five injections, one
treatment&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Six sessions of local infiltration in the
tumour scar tissue are required. The product&amp;rsquo;s claim is specific: &amp;ldquo;&lt;i&gt;reducing
the risk of relapse and increasing the time to relapse in cats with
fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in
addition to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;After reconstitution, five subcutaneous
injections (0.2 ml each) are made in and around the tumour excision site: &amp;ldquo;&lt;i&gt;one
injection at each corner and one injection at the centre of a 5 cm x 5 cm
square centred on the middle of the surgical scar&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;A treatment course consists of four
sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment
sessions at 2-week intervals (D35, D49). Treatment should start the day before
commencing radiation therapy, preferably within one month after surgical
excision.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, no particular precautions are
necessary for administration, as &amp;ldquo;&lt;i&gt;canarypox recombinants are safe, and
feline IL-2 has a very low biological activity in humans&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;First surgical attempt = main prognostic
factor&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;An association between injections and
the development of feline injection-site sarcomas (FISS) was first observed in
the 1980s&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;, recalled Ana Lara (Royal Veterinary
College, UK). Subsequent studies showed a link with a range of injectable drugs
triggering local inflammation followed by an abnormal proliferation of
fibroblasts and myofibroblasts. &amp;ldquo;&lt;i&gt;These sarcomas were found to be highly
locally infiltrative but with a relatively low (0-24%) metastatic rate&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Although it is a neoplasia that is associated to veterinary
practice, there is a potential for prevention and early diagnosis: &amp;ldquo;&lt;i&gt;we know
the risk-population (those receiving injections) and the location (site of
injection)&amp;rdquo;. &lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;For these reasons, a benefit-risk
analysis is required prior to vaccination while vaccinate in the distal
extremities should be considered to maximise the chance of cure in the advent
of FISS.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;If FISS is suspected, never perform
excisional biopsy - it has a detrimental impact on prognosis&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; warned Dr Lara. &amp;ldquo;&lt;i&gt;In fact, the number one prognostic factor is
the first attempt at surgery - which should be aggressive: margins should be
4-5 cm wide and at least 2 fascial layers deep&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;She also recalled the 3-2-1 rule: &amp;ldquo;&lt;i&gt;biopsy
if the lump persists for more than 3 months, if it is larger than 2 cm or if it
has appeared within 1 month of injection&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Adding
radiotherapy increases the disease-free interval, but not the cure rate &amp;ndash; and
is not available in all European countries. Chemotherapy may be of interest in
cats with unresectable or metastatic tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;bull;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span style="text-decoration:underline;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;

&lt;div style="font-size: 90%;"&gt;Tags: cats, sarcoma, fibroma, fibrosarcoma, oncology, immunotherapy&lt;/div&gt;
</description></item><item><title>Innovative treatment for Feline Injection Site Sarcoma to be launched this autumn</title><link>https://www.vetsurgeon.org/w/veterinary-research/88/innovative-treatment-for-feline-fibrosarcoma-to-be-launched-this-autumn/revision/4</link><pubDate>Tue, 11 Jun 2013 12:06:15 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:493a21f5-d73a-4fac-80ee-8d4f00aac816</guid><dc:creator>kdelange</dc:creator><description>Revision 4 posted to Abstracts, Short Communications &amp;amp; Research by kdelange on 6/11/2013 12:06:15 PM&lt;br /&gt;
&lt;p&gt;&lt;span style="font-weight:normal;"&gt;&lt;span lang="EN-GB"&gt;Lisbon, 29 May 2013 - &amp;ldquo;&lt;i&gt;On average, European veterinary
practitioners see between two and three cases of feline sarcoma each year&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; reported Pascal Fayard, European marketing manager, citing a
survey held among 500 general practitioners in five countries. Speaking at a
Merial Conference held in Lisbon on 29 of May, on the eve of the congress of
European Society of Veterinary Oncology, he announced the European-wide launch,
coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the
treatment of fibrosarcoma in cats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&lt;a href="/cfs-file.ashx/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg"&gt;&lt;img src="/resized-image.ashx/__size/550x0/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg" border="0" alt="" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;i&gt;Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&amp;amp;D Merial), Catherine P&amp;eacute;pin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion animals, Merial), Ana Lara (Royal Veterinary College, London), Herv&amp;eacute; Poulet (R&amp;amp;D Merial), Jolle Kirpensteijn (Utrecht University, moderator).&lt;/i&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;Interleukin: stimulating anti-tumour
defence&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;Interleukin 2 (IL-2) stimulates the
growth and activity of T-lymphocytes and natural killer cells, the production of
other cytokines like interferon gamma (IFN&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;&lt;span&gt;g&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;) and improves the specific tumour-protective memory immune
response&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; explained Herv&amp;eacute; Poulet, Head of bio
development Europe and R&amp;amp;D leader at Merial. &amp;ldquo;&lt;i&gt;In humans, high-dose
systemic IL-2 has been approved for the treatment of metastatic melanoma and
renal cell carcinoma&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, large doses of systemic IL-2 are
associated with several toxic side effects, including the capillary leak
syndrome while its clinical efficacy is hampered by the short half-life of IL-2
(a few days). To overcome this, several local IL-2-delivery systems have been
studied, including free recombinant IL-2, or bound to DNA plasmids, viral
vectors, IL-2 secreting cells and antibody-targeted IL. The therapeutic effects
of local IL-2 therapy have been demonstrated in several cancers, including
equine sarcoids, canine melanoma and non-resectable mast cell tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;For feline fibrosarcoma, we chose an
IL-2 expressing canarypox virus vector (ALVAC&lt;sup&gt;&amp;reg;&lt;/sup&gt;): it is very safe as
it does not replicate and expresses IL-2 locally. It was found to be an
efficacious adjunct treatment to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; Dr Poulet concluded.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Reducing the risk of relapse by 65%&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Results of a monocentric clinical trial
were presented by Dominique Jas (Merial R&amp;amp;D) to confirm the efficacy and
safety of the product. Seventy-one cats with a first occurrence of feline
fibrosarcoma were referred for post-surgical radiotherapy. They were assigned
to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2
treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery
+ radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not
necessarily done in referral practices. However, the percentage of cats with
dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14,
D35, D49) was initiated the day before the start of radiotherapy (D1 and D3).
Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24
months. The high-dose group &amp;ndash; to test safety &amp;ndash; was monitored for a year, the
low-dose group &amp;ndash; to test efficacy &amp;ndash; for two years.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Local ALVAC IL-2-treated cats showed a
significantly longer median time to relapse (&amp;gt;730 days) than in the
reference treatment group (287 days). Results also showed a significant
reduction of relapse risk compared to the control group, both after one year
(56%) and after two years (65%). Oncept IL-2 was well tolerated, and the time
without relapse was significantly increased with no alteration of quality of
life.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;This study showed that the control
group, that did not undergo immunotherapy, did had poorer results than either
treatment group &amp;ndash; in spite of the cats receiving a total of thirty injections&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;quot; Dr Jas confirmed, in answer to the question whether
treatment injections were not a risk factors for the development of FISS. &lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Colleagues from Spain, where there is no
radiotherapy available for pets, asked about the possible benefits in cats with
surgery alone. &amp;ldquo;&lt;i&gt;We currently only have a claim for an adjunct therapy to surgery
and radiotherapy,&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt; stressed Dr Jas, but she added
that this was currently being investigated.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;An EU-wide launch this autumn&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We&amp;rsquo;re very excited and proud to announce
the forthcoming launch of a new immunotherapy, a recombinant canarypox virus
expressing feline IL-2 at the site of injection, added Catherine P&amp;eacute;pin,
Merial&amp;rsquo;s technical manager for companion animals. &amp;ldquo;The claim is for an adjunct
treatment in cats with fibrosarcoma (2-5 cm diameter) without metastasis or
lymph node involvement, in order to reduce the risk of relapse and to increase
the relapse-free interval.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Oncept IL-2, result of a long-standing
collaboration between Merial R&amp;amp;D and leading oncology experts, is the first
cancer immunotherapeutic drug approved for veterinary use in Europe.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We expect to launch Oncept IL-2 throughout
the EU this coming autumn, added Pascal Fayard. He also presented the packaging
(&amp;ldquo;&lt;i&gt;one box contains 6 doses, equal to one course of treatment&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;) and storage requirements (&amp;ldquo;&lt;i&gt;in the refrigerator, just like
vaccines&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;). However, the expected retail price was
not yet known &amp;ndash; but would no doubt be &amp;ldquo;&lt;i&gt;well over a hundred euros&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Oncept IL-2:&amp;nbsp;Six sessions, five injections, one
treatment&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Six sessions of local infiltration in the
tumour scar tissue are required. The product&amp;rsquo;s claim is specific: &amp;ldquo;&lt;i&gt;reducing
the risk of relapse and increasing the time to relapse in cats with
fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in
addition to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;After reconstitution, five subcutaneous
injections (0.2 ml each) are made in and around the tumour excision site: &amp;ldquo;&lt;i&gt;one
injection at each corner and one injection at the centre of a 5 cm x 5 cm
square centred on the middle of the surgical scar&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;A treatment course consists of four
sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment
sessions at 2-week intervals (D35, D49). Treatment should start the day before
commencing radiation therapy, preferably within one month after surgical
excision.&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, no particular precautions are
necessary for administration, as &amp;ldquo;&lt;i&gt;canarypox recombinants are safe, and
feline IL-2 has a very low biological activity in humans&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;First surgical attempt = main prognostic
factor&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;An association between injections and
the development of feline injection-site sarcomas (FISS) was first observed in
the 1980s&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;, recalled Ana Lara (Royal Veterinary
College, UK). Subsequent studies showed a link with a range of injectable drugs
triggering local inflammation followed by an abnormal proliferation of
fibroblasts and myofibroblasts. &amp;ldquo;&lt;i&gt;These sarcomas were found to be highly
locally infiltrative but with a relatively low (0-24%) metastatic rate&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Although it is a neoplasia that is associated to veterinary
practice, there is a potential for prevention and early diagnosis: &amp;ldquo;&lt;i&gt;we know
the risk-population (those receiving injections) and the location (site of
injection)&amp;rdquo;. &lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;For these reasons, a benefit-risk
analysis is required prior to vaccination while vaccinate in the distal
extremities should be considered to maximise the chance of cure in the advent
of FISS.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;If FISS is suspected, never perform
excisional biopsy - it has a detrimental impact on prognosis&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; warned Dr Lara. &amp;ldquo;&lt;i&gt;In fact, the number one prognostic factor is
the first attempt at surgery - which should be aggressive: margins should be
4-5 cm wide and at least 2 fascial layers deep&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;She also recalled the 3-2-1 rule: &amp;ldquo;&lt;i&gt;biopsy
if the lump persists for more than 3 months, if it is larger than 2 cm or if it
has appeared within 1 month of injection&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Adding
radiotherapy increases the disease-free interval, but not the cure rate &amp;ndash; and
is not available in all European countries. Chemotherapy may be of interest in
cats with unresectable or metastatic tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;bull;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span style="text-decoration:underline;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;

&lt;div style="font-size: 90%;"&gt;Tags: cats, sarcoma, fibroma, fibrosarcoma, oncology, immunotherapy&lt;/div&gt;
</description></item><item><title>Innovative treatment for Feline Injection Site Sarcoma to be launched this autumn</title><link>https://www.vetsurgeon.org/w/veterinary-research/88/innovative-treatment-for-feline-fibrosarcoma-to-be-launched-this-autumn/revision/3</link><pubDate>Tue, 11 Jun 2013 12:04:34 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:493a21f5-d73a-4fac-80ee-8d4f00aac816</guid><dc:creator>kdelange</dc:creator><description>Revision 3 posted to Abstracts, Short Communications &amp;amp; Research by kdelange on 6/11/2013 12:04:34 PM&lt;br /&gt;
&lt;p&gt;&lt;span style="font-weight:normal;"&gt;&lt;span lang="EN-GB"&gt;Lisbon, 29 May 2013 - &amp;ldquo;&lt;i&gt;On average, European veterinary
practitioners see between two and three cases of feline sarcoma each year&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; reported Pascal Fayard, European marketing manager, citing a
survey held among 500 general practitioners in five countries. Speaking at a
Merial Conference held in Lisbon on 29 of May, on the eve of the congress of
European Society of Veterinary Oncology, he announced the European-wide launch,
coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the
treatment of fibrosarcoma in cats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&lt;a href="/cfs-file.ashx/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg"&gt;&lt;img border="0" src="/resized-image.ashx/__size/550x0/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg" alt="" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;i&gt;Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&amp;amp;D Merial), Catherine P&amp;eacute;pin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion animals, Merial), Ana Lara (Royal Veterinary College, London), Herv&amp;eacute; Poulet (R&amp;amp;D Merial), Jolle Kirpensteijn (Utrecht University, moderator).&lt;/i&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;Interleukin: stimulating anti-tumour
defence&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;Interleukin 2 (IL-2) stimulates the
growth and activity of T-lymphocytes and natural killer cells, the production of
other cytokines like interferon gamma (IFN&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;&lt;span&gt;g&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;) and improves the specific tumour-protective memory immune
response&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; explained Herv&amp;eacute; Poulet, Head of bio
development Europe and R&amp;amp;D leader at Merial. &amp;ldquo;&lt;i&gt;In humans, high-dose
systemic IL-2 has been approved for the treatment of metastatic melanoma and
renal cell carcinoma&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, large doses of systemic IL-2 are
associated with several toxic side effects, including the capillary leak
syndrome while its clinical efficacy is hampered by the short half-life of IL-2
(a few days). To overcome this, several local IL-2-delivery systems have been
studied, including free recombinant IL-2, or bound to DNA plasmids, viral
vectors, IL-2 secreting cells and antibody-targeted IL. The therapeutic effects
of local IL-2 therapy have been demonstrated in several cancers, including
equine sarcoids, canine melanoma and non-resectable mast cell tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;For feline fibrosarcoma, we chose an
IL-2 expressing canarypox virus vector (ALVAC&lt;sup&gt;&amp;reg;&lt;/sup&gt;): it is very safe as
it does not replicate and expresses IL-2 locally. It was found to be an
efficacious adjunct treatment to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; Dr Poulet concluded.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Reducing the risk of relapse by 65%&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Results of a monocentric clinical trial
were presented by Dominique Jas (Merial R&amp;amp;D) to confirm the efficacy and
safety of the product. Seventy-one cats with a first occurrence of feline
fibrosarcoma were referred for post-surgical radiotherapy. They were assigned
to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2
treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery
+ radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not
necessarily done in referral practices. However, the percentage of cats with
dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14,
D35, D49) was initiated the day before the start of radiotherapy (D1 and D3).
Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24
months. The high-dose group &amp;ndash; to test safety &amp;ndash; was monitored for a year, the
low-dose group &amp;ndash; to test efficacy &amp;ndash; for two years.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Local ALVAC IL-2-treated cats showed a
significantly longer median time to relapse (&amp;gt;730 days) than in the
reference treatment group (287 days). Results also showed a significant
reduction of relapse risk compared to the control group, both after one year
(56%) and after two years (65%). Oncept IL-2 was well tolerated, and the time
without relapse was significantly increased with no alteration of quality of
life.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;This study showed that the control
group, that did not undergo immunotherapy, did had poorer results than either
treatment group &amp;ndash; in spite of the cats receiving a total of thirty injections&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;quot; Dr Jas confirmed, in answer to the question whether
treatment injections were not a risk factors for the development of FISS. &lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Colleagues from Spain, where there is no
radiotherapy available for pets, asked about the possible benefits in cats with
surgery alone. &amp;ldquo;&lt;i&gt;We currently only have a claim for an adjunct therapy to surgery
and radiotherapy,&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt; stressed Dr Jas, but she added
that this was currently being investigated.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;An EU-wide launch this autumn&lt;strong&gt;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We&amp;rsquo;re very excited and proud to announce
the forthcoming launch of a new immunotherapy, a recombinant canarypox virus
expressing feline IL-2 at the site of injection, added Catherine P&amp;eacute;pin,
Merial&amp;rsquo;s technical manager for companion animals. &amp;ldquo;The claim is for an adjunct
treatment in cats with fibrosarcoma (2-5 cm diameter) without metastasis or
lymph node involvement, in order to reduce the risk of relapse and to increase
the relapse-free interval.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Oncept IL-2, result of a long-standing
collaboration between Merial R&amp;amp;D and leading oncology experts, is the first
cancer immunotherapeutic drug approved for veterinary use in Europe.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We expect to launch Oncept IL-2 throughout
the EU this coming autumn, added Pascal Fayard. He also presented the packaging
(&amp;ldquo;&lt;i&gt;one box contains 6 doses, equal to one course of treatment&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;) and storage requirements (&amp;ldquo;&lt;i&gt;in the refrigerator, just like
vaccines&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;). However, the expected retail price was
not yet known &amp;ndash; but would no doubt be &amp;ldquo;&lt;i&gt;well over a hundred euros&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Oncept IL-2:&amp;nbsp;Six sessions, five injections, one
treatment&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Six sessions of local infiltration in the
tumour scar tissue are required. The product&amp;rsquo;s claim is specific: &amp;ldquo;&lt;i&gt;reducing
the risk of relapse and increasing the time to relapse in cats with
fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in
addition to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;After reconstitution, five subcutaneous
injections (0.2 ml each) are made in and around the tumour excision site: &amp;ldquo;&lt;i&gt;one
injection at each corner and one injection at the centre of a 5 cm x 5 cm
square centred on the middle of the surgical scar&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;A treatment course consists of four
sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment
sessions at 2-week intervals (D35, D49). Treatment should start the day before
commencing radiation therapy, preferably within one month after surgical
excision.&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, no particular precautions are
necessary for administration, as &amp;ldquo;&lt;i&gt;canarypox recombinants are safe, and
feline IL-2 has a very low biological activity in humans&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;First surgical attempt = main prognostic
factor&lt;strong&gt;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;An association between injections and
the development of feline injection-site sarcomas (FISS) was first observed in
the 1980s&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;, recalled Ana Lara (Royal Veterinary
College, UK). Subsequent studies showed a link with a range of injectable drugs
triggering local inflammation followed by an abnormal proliferation of
fibroblasts and myofibroblasts. &amp;ldquo;&lt;i&gt;These sarcomas were found to be highly
locally infiltrative but with a relatively low (0-24%) metastatic rate&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Although it is a neoplasia that is associated to veterinary
practice, there is a potential for prevention and early diagnosis: &amp;ldquo;&lt;i&gt;we know
the risk-population (those receiving injections) and the location (site of
injection)&amp;rdquo;. &lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;For these reasons, a benefit-risk
analysis is required prior to vaccination while vaccinate in the distal
extremities should be considered to maximise the chance of cure in the advent
of FISS.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;If FISS is suspected, never perform
excisional biopsy - it has a detrimental impact on prognosis&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; warned Dr Lara. &amp;ldquo;&lt;i&gt;In fact, the number one prognostic factor is
the first attempt at surgery - which should be aggressive: margins should be
4-5 cm wide and at least 2 fascial layers deep&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;She also recalled the 3-2-1 rule: &amp;ldquo;&lt;i&gt;biopsy
if the lump persists for more than 3 months, if it is larger than 2 cm or if it
has appeared within 1 month of injection&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Adding
radiotherapy increases the disease-free interval, but not the cure rate &amp;ndash; and
is not available in all European countries. Chemotherapy may be of interest in
cats with unresectable or metastatic tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;bull;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span style="text-decoration:underline;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&amp;nbsp;&lt;/p&gt;
&amp;lt;!--EndFragment--&amp;gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;

&lt;div style="font-size: 90%;"&gt;Tags: cats, sarcoma, fibroma, fibrosarcoma, oncology, immunotherapy&lt;/div&gt;
</description></item><item><title>Innovative treatment for Feline Injection Site Sarcoma to be launched this autumn</title><link>https://www.vetsurgeon.org/w/veterinary-research/88/innovative-treatment-for-feline-fibrosarcoma-to-be-launched-this-autumn/revision/2</link><pubDate>Tue, 11 Jun 2013 12:02:34 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:493a21f5-d73a-4fac-80ee-8d4f00aac816</guid><dc:creator>kdelange</dc:creator><description>Revision 2 posted to Abstracts, Short Communications &amp;amp; Research by kdelange on 6/11/2013 12:02:34 PM&lt;br /&gt;
&lt;p&gt;
&amp;lt;!--[if gte mso 9]&amp;gt;&amp;lt;xml&amp;gt;
 &amp;lt;o:DocumentProperties&amp;gt;
  &amp;lt;o:Template&amp;gt;Normal&amp;lt;/o:Template&amp;gt;
  &amp;lt;o:Revision&amp;gt;0&amp;lt;/o:Revision&amp;gt;
  &amp;lt;o:TotalTime&amp;gt;0&amp;lt;/o:TotalTime&amp;gt;
  &amp;lt;o:Created&amp;gt;2013-05-28T07:27:00Z&amp;lt;/o:Created&amp;gt;
  &amp;lt;o:LastSaved&amp;gt;2013-05-28T14:08:00Z&amp;lt;/o:LastSaved&amp;gt;
  &amp;lt;o:Pages&amp;gt;1&amp;lt;/o:Pages&amp;gt;
  &amp;lt;o:Words&amp;gt;1214&amp;lt;/o:Words&amp;gt;
  &amp;lt;o:Characters&amp;gt;6560&amp;lt;/o:Characters&amp;gt;
  &amp;lt;o:Lines&amp;gt;113&amp;lt;/o:Lines&amp;gt;
  &amp;lt;o:Paragraphs&amp;gt;22&amp;lt;/o:Paragraphs&amp;gt;
  &amp;lt;o:CharactersWithSpaces&amp;gt;8503&amp;lt;/o:CharactersWithSpaces&amp;gt;
  &amp;lt;o:Version&amp;gt;11.768&amp;lt;/o:Version&amp;gt;
 &amp;lt;/o:DocumentProperties&amp;gt;
 &amp;lt;o:OfficeDocumentSettings&amp;gt;
  &amp;lt;o:AllowPNG /&amp;gt;
 &amp;lt;/o:OfficeDocumentSettings&amp;gt;
&amp;lt;/xml&amp;gt;&amp;lt;![endif]--&amp;gt;&amp;lt;!--[if gte mso 9]&amp;gt;&amp;lt;xml&amp;gt;
 &amp;lt;w:WordDocument&amp;gt;
  &amp;lt;w:Zoom&amp;gt;0&amp;lt;/w:Zoom&amp;gt;
  &amp;lt;w:DoNotShowRevisions /&amp;gt;
  &amp;lt;w:DoNotPrintRevisions /&amp;gt;
  &amp;lt;w:HyphenationZone&amp;gt;21&amp;lt;/w:HyphenationZone&amp;gt;
  &amp;lt;w:DisplayHorizontalDrawingGridEvery&amp;gt;0&amp;lt;/w:DisplayHorizontalDrawingGridEvery&amp;gt;
  &amp;lt;w:DisplayVerticalDrawingGridEvery&amp;gt;0&amp;lt;/w:DisplayVerticalDrawingGridEvery&amp;gt;
  &amp;lt;w:UseMarginsForDrawingGridOrigin /&amp;gt;
 &amp;lt;/w:WordDocument&amp;gt;
&amp;lt;/xml&amp;gt;&amp;lt;![endif]--&amp;gt;
&amp;lt;!--StartFragment--&amp;gt;
&lt;/p&gt;
&lt;h2&gt;
&lt;p&gt;&lt;span style="font-weight:normal;"&gt;&lt;span lang="EN-GB"&gt;Lisbon, 29 May 2013 - &amp;ldquo;&lt;i&gt;On average, European veterinary
practitioners see between two and three cases of feline sarcoma each year&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; reported Pascal Fayard, European marketing manager, citing a
survey held among 500 general practitioners in five countries. Speaking at a
Merial Conference held in Lisbon on 29 of May, on the eve of the congress of
European Society of Veterinary Oncology, he announced the European-wide launch,
coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the
treatment of fibrosarcoma in cats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/h2&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&lt;a href="/cfs-file.ashx/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg"&gt;&lt;img src="/resized-image.ashx/__size/550x0/__key/CommunityServer.Wikis.Components.Files/veterinary-research/6283.SPEAKERS_5F00_ONCEPT_5F00_CONF2013.jpg" border="0" alt="" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;i&gt;Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&amp;amp;D Merial), Catherine P&amp;eacute;pin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion animals, Merial), Ana Lara (Royal Veterinary College, London), Herv&amp;eacute; Poulet (R&amp;amp;D Merial), Jolle Kirpensteijn (Utrecht University, moderator).&lt;/i&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;Interleukin: stimulating anti-tumour
defence&lt;b&gt;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/b&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;Interleukin 2 (IL-2) stimulates the
growth and activity of T-lymphocytes and natural killer cells, the production of
other cytokines like interferon gamma (IFN&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;&lt;span&gt;g&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&lt;i&gt;) and improves the specific tumour-protective memory immune
response&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; explained Herv&amp;eacute; Poulet, Head of bio
development Europe and R&amp;amp;D leader at Merial. &amp;ldquo;&lt;i&gt;In humans, high-dose
systemic IL-2 has been approved for the treatment of metastatic melanoma and
renal cell carcinoma&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, large doses of systemic IL-2 are
associated with several toxic side effects, including the capillary leak
syndrome while its clinical efficacy is hampered by the short half-life of IL-2
(a few days). To overcome this, several local IL-2-delivery systems have been
studied, including free recombinant IL-2, or bound to DNA plasmids, viral
vectors, IL-2 secreting cells and antibody-targeted IL. The therapeutic effects
of local IL-2 therapy have been demonstrated in several cancers, including
equine sarcoids, canine melanoma and non-resectable mast cell tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;For feline fibrosarcoma, we chose an
IL-2 expressing canarypox virus vector (ALVAC&lt;sup&gt;&amp;reg;&lt;/sup&gt;): it is very safe as
it does not replicate and expresses IL-2 locally. It was found to be an
efficacious adjunct treatment to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; Dr Poulet concluded.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Reducing the risk of relapse by 65%&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Results of a monocentric clinical trial
were presented by Dominique Jas (Merial R&amp;amp;D) to confirm the efficacy and
safety of the product. Seventy-one cats with a first occurrence of feline
fibrosarcoma were referred for post-surgical radiotherapy. They were assigned
to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2
treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery
+ radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not
necessarily done in referral practices. However, the percentage of cats with
dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14,
D35, D49) was initiated the day before the start of radiotherapy (D1 and D3).
Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24
months. The high-dose group &amp;ndash; to test safety &amp;ndash; was monitored for a year, the
low-dose group &amp;ndash; to test efficacy &amp;ndash; for two years.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Local ALVAC IL-2-treated cats showed a
significantly longer median time to relapse (&amp;gt;730 days) than in the
reference treatment group (287 days). Results also showed a significant
reduction of relapse risk compared to the control group, both after one year
(56%) and after two years (65%). Oncept IL-2 was well tolerated, and the time
without relapse was significantly increased with no alteration of quality of
life.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;This study showed that the control
group, that did not undergo immunotherapy, did had poorer results than either
treatment group &amp;ndash; in spite of the cats receiving a total of thirty injections&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;quot; Dr Jas confirmed, in answer to the question whether
treatment injections were not a risk factors for the development of FISS. &lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Colleagues from Spain, where there is no
radiotherapy available for pets, asked about the possible benefits in cats with
surgery alone. &amp;ldquo;&lt;i&gt;We currently only have a claim for an adjunct therapy to surgery
and radiotherapy,&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt; stressed Dr Jas, but she added
that this was currently being investigated.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;An EU-wide launch this autumn&lt;b&gt;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/b&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We&amp;rsquo;re very excited and proud to announce
the forthcoming launch of a new immunotherapy, a recombinant canarypox virus
expressing feline IL-2 at the site of injection, added Catherine P&amp;eacute;pin,
Merial&amp;rsquo;s technical manager for companion animals. &amp;ldquo;The claim is for an adjunct
treatment in cats with fibrosarcoma (2-5 cm diameter) without metastasis or
lymph node involvement, in order to reduce the risk of relapse and to increase
the relapse-free interval.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Oncept IL-2, result of a long-standing
collaboration between Merial R&amp;amp;D and leading oncology experts, is the first
cancer immunotherapeutic drug approved for veterinary use in Europe.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;We expect to launch Oncept IL-2 throughout
the EU this coming autumn, added Pascal Fayard. He also presented the packaging
(&amp;ldquo;&lt;i&gt;one box contains 6 doses, equal to one course of treatment&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;) and storage requirements (&amp;ldquo;&lt;i&gt;in the refrigerator, just like
vaccines&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;). However, the expected retail price was
not yet known &amp;ndash; but would no doubt be &amp;ldquo;&lt;i&gt;well over a hundred euros&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;Oncept IL-2:&amp;nbsp;Six sessions, five injections, one
treatment&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;Six sessions of local infiltration in the
tumour scar tissue are required. The product&amp;rsquo;s claim is specific: &amp;ldquo;&lt;i&gt;reducing
the risk of relapse and increasing the time to relapse in cats with
fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in
addition to surgery and radiotherapy&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;After reconstitution, five subcutaneous
injections (0.2 ml each) are made in and around the tumour excision site: &amp;ldquo;&lt;i&gt;one
injection at each corner and one injection at the centre of a 5 cm x 5 cm
square centred on the middle of the surgical scar&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;A treatment course consists of four
sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment
sessions at 2-week intervals (D35, D49). Treatment should start the day before
commencing radiation therapy, preferably within one month after surgical
excision.&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;However, no particular precautions are
necessary for administration, as &amp;ldquo;&lt;i&gt;canarypox recombinants are safe, and
feline IL-2 has a very low biological activity in humans&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;.&lt;/span&gt;&lt;/p&gt;
&lt;h3&gt;&lt;span lang="EN-GB"&gt;First surgical attempt = main prognostic
factor&lt;b&gt;&amp;lt;o:p&amp;gt;&amp;lt;/o:p&amp;gt;&lt;/b&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;An association between injections and
the development of feline injection-site sarcomas (FISS) was first observed in
the 1980s&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;&amp;rdquo;, recalled Ana Lara (Royal Veterinary
College, UK). Subsequent studies showed a link with a range of injectable drugs
triggering local inflammation followed by an abnormal proliferation of
fibroblasts and myofibroblasts. &amp;ldquo;&lt;i&gt;These sarcomas were found to be highly
locally infiltrative but with a relatively low (0-24%) metastatic rate&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Although it is a neoplasia that is associated to veterinary
practice, there is a potential for prevention and early diagnosis: &amp;ldquo;&lt;i&gt;we know
the risk-population (those receiving injections) and the location (site of
injection)&amp;rdquo;. &lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;For these reasons, a benefit-risk
analysis is required prior to vaccination while vaccinate in the distal
extremities should be considered to maximise the chance of cure in the advent
of FISS.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;ldquo;&lt;i&gt;If FISS is suspected, never perform
excisional biopsy - it has a detrimental impact on prognosis&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;,&amp;rdquo; warned Dr Lara. &amp;ldquo;&lt;i&gt;In fact, the number one prognostic factor is
the first attempt at surgery - which should be aggressive: margins should be
4-5 cm wide and at least 2 fascial layers deep&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;She also recalled the 3-2-1 rule: &amp;ldquo;&lt;i&gt;biopsy
if the lump persists for more than 3 months, if it is larger than 2 cm or if it
has appeared within 1 month of injection&lt;/i&gt;&lt;/span&gt;&lt;span lang="EN-GB"&gt;.&amp;rdquo; Adding
radiotherapy increases the disease-free interval, but not the cure rate &amp;ndash; and
is not available in all European countries. Chemotherapy may be of interest in
cats with unresectable or metastatic tumours.&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span lang="EN-GB"&gt;&amp;bull;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&lt;span style="text-decoration:underline;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class="MsoNormal"&gt;&amp;nbsp;&lt;/p&gt;
&amp;lt;!--EndFragment--&amp;gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;

&lt;div style="font-size: 90%;"&gt;Tags: cats, sarcoma, fibroma, fibrosarcoma, oncology, immunotherapy&lt;/div&gt;
</description></item><item><title>Property Letting Services for Forum members</title><link>https://www.vetsurgeon.org/w/veterinary-research/1138/property-letting-services-for-forum-members</link><pubDate>Thu, 14 Feb 2013 17:37:03 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:051bc0fe-19e4-4dbf-ab2f-5eca3a7f10c9</guid><dc:creator>Neal Palk</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by Neal Palk on 2/14/2013 5:37:03 PM&lt;br /&gt;
&lt;p&gt;I hope a quick plug for a new service is OK here (Arlo please remove/relocate/chastise as appropriate).&lt;/p&gt;
&lt;p&gt;Via my company I have signed up as a lettings agent for a large national lettings company so would be delighted to hear from any members on here who have rooms, apartments, houses or maybe even commercial premises for which a tenant is needed.&lt;/p&gt;
&lt;p&gt;The rates are low and the service extends to the administration of rent, lease, EPCs, gas safety, tenant referencing etc all at fixed (and communicated in advance!) prices. &lt;/p&gt;
&lt;p&gt;Most importantly, the tenant find service is charged ONLY once a tenant has been found and a tenancy agreed and the first month&amp;#39;s rent paid. So, no tenant = no fee!&lt;/p&gt;
&lt;p&gt;UK coverage - please post up or message me if you&amp;#39;d like to discuss.&lt;/p&gt;
&lt;p&gt;Of course if you or perhaps a newly recruited vet/nurse is in need of accommodation I&amp;#39;d be delighted to help also.&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>Employment Law Changes Oct 2012</title><link>https://www.vetsurgeon.org/w/veterinary-research/1127/employment-law-changes-oct-2012</link><pubDate>Wed, 26 Sep 2012 13:26:09 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:a3ec36fb-7779-4f51-b7aa-60e2547c4fe4</guid><dc:creator>Neal Palk</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by Neal Palk on 9/26/2012 1:26:09 PM&lt;br /&gt;
&lt;p&gt;Nothing too startling or unexpected....&lt;/p&gt;
&lt;p&gt;1. Minimum wage increases to &amp;pound;6.19 per hour for 21+. The apprentice rate increases to &amp;pound;2.65, but the Youth Rate remains unchanged.&lt;/p&gt;
&lt;p&gt;2. The auto-enrollment to a qualifying workplace pension scheme or NEST begins - but ONLY for large organisations employing 120k+ people.&lt;/p&gt;
&lt;p&gt;3. The default retirement age use will end! No more compulsory retirement at 65.....&lt;/p&gt;
&lt;p&gt;Worth reading up on point 2 ready for 2013 implementation and be VERY alert to the implications of 3.!&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>Queen's Speech - Early indications</title><link>https://www.vetsurgeon.org/w/veterinary-research/1116/queen-s-speech-early-indications</link><pubDate>Wed, 09 May 2012 15:53:01 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:65e54a89-88d7-4181-889f-25482e3b7944</guid><dc:creator>Neal Palk</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by Neal Palk on 5/9/2012 3:53:01 PM&lt;br /&gt;
&lt;p&gt;The ceremony of the Queen&amp;#39;s Speech usually overshadows the nitty-gritty of what&amp;#39;s really on the plans, but from what I&amp;#39;ve read, the &amp;#39;employment headlines&amp;#39; are:&lt;/p&gt;
&lt;p&gt;&amp;nbsp;- Some actions on executive pay.......unlikely to affect anyone on this Forum directly!&lt;/p&gt;
&lt;p&gt;- Further adjustments to the workplace dispute processes which look to be introducing early/earlier conciliation in-house to avoid ET hearings etc subsequently. No bad thing at first sight, but may shift more burden ONTO employers?&lt;/p&gt;
&lt;p&gt;- The Children &amp;amp; Families Bill loosens up some parental rights and introduces parental leave &amp;#39;swapping&amp;#39; and earlier returns to work for Mothers.&lt;/p&gt;
&lt;p&gt;The headline quote reads &amp;#39;Legislation will be introduced to reduce burdens on business by repealing unnecessary legislation&amp;#39;.............I&amp;#39;ve been waiting 30 years for someone to do that!&lt;/p&gt;
&lt;p&gt;Summary - keep an eye out for changes to the internal grievance procedure &amp;#39;best practices&amp;#39;.......&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item><item><title>Unfair Dismissal Eligibility - Changes 6th April</title><link>https://www.vetsurgeon.org/w/veterinary-research/1107/unfair-dismissal-eligibility-changes-6th-april</link><pubDate>Wed, 14 Mar 2012 15:38:02 GMT</pubDate><guid isPermaLink="false">146601cc-3922-4be7-9974-7e1d4e45a66b:cffaf386-b291-4bea-94f7-f7c6298d690a</guid><dc:creator>Neal Palk</dc:creator><description>Current Revision posted to Abstracts, Short Communications &amp;amp; Research by Neal Palk on 3/14/2012 3:38:02 PM&lt;br /&gt;
&lt;p&gt;Following from the previous Wiki, the return to a 2 year qualifying period for unfair dismissal claims commences April 6th 2012 - BUT note that the clock is zeroed at April 6th, so someone who commenced employment (say) May 1st 2011 will only need a one year qualifying period.&lt;/p&gt;
&lt;p&gt;The above of course does not include dismissals where there is no qualifying period currently - so no change in some circumstances (ERA 1996)&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;
</description></item></channel></rss>